Stay updated on Taletrectinib ROS1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Taletrectinib ROS1+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-11-01T16:02:32.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    0.6%
    Check dated 2026-10-25T15:28:59.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision changed from v3.7.1 to v3.7.2, with no visible change to the study record.
    Difference
    0.1%
    Check dated 2026-10-18T15:27:38.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.1%
    Check dated 2026-10-11T15:23:54.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.7.0 is added to the record history, and the previous revision v3.6.6 is removed from the displayed history.
    Difference
    0.1%
    Check dated 2026-09-20T19:44:04.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    A new revision label v3.6.6 has been added to the study's record history. The previous revision label v3.6.5 is removed from the changes shown in the history.
    Difference
    0.1%
    Check dated 2026-08-30T06:23:10.000Z thumbnail image

Stay in the know with updates to Taletrectinib ROS1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.